<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6736">
  <stage>Registered</stage>
  <submitdate>11/06/2015</submitdate>
  <approvaldate>11/06/2015</approvaldate>
  <nctid>NCT02471638</nctid>
  <trial_identification>
    <studytitle>PQ Bypass Systems for Femoropopliteal Bypass II</studytitle>
    <scientifictitle>PQ Bypass Systems for Femoropopliteal Bypass II (PQB 4 FP II)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>STP 115</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Arterial Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - PQ Bypass System for Femoropopliteal Bypass

Experimental: Single arm study - PQ Bypass System for Femoropopliteal Bypass to complete percutaneous fem-pop bypass


Treatment: devices: PQ Bypass System for Femoropopliteal Bypass
To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Performance Endpoint (Rate of primary patency) - Rate of primary patency. Primary patency defined as: no evidence of clinically significant stenosis (=50%) within the stent graft or immediately above or below the treated arterial segment based on duplex ultrasound (systolic velocity ratio of &gt;2.5).</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Willing and able to provide informed consent

          -  Age 18 or older

          -  Rutherford Classification of 3-5

          -  Patent iliac and femoral arteries/veins and access vessels, of sufficient size and
             morphology (including tortuosity), to allow endovascular access with 8 Fr. introducer
             sheath

          -  Femoro-popliteal lesions =10 cm in length considered to be:

               -  Chronic total occlusion (100% stenosis)

               -  Diffuse stenosis (&gt;50% stenosis) with moderate to heavy calcification

               -  In-stent restenosis (&gt;50% stenosis)

          -  Proximal and distal target vessels are 5.4-7.0 mm in diameter

          -  Orifice and proximal 1 cm of SFA is patent

          -  Patent popliteal artery 3 cm proximal to tibial plateau

          -  At least 1 patent tibial artery to the foot

          -  Patent femoral vein = 10 mm in diameter or duplicate femoral vein

          -  Subject has &gt; one year life expectancy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Bypass length required &gt; 30 cm

          -  History of deep vein thrombosis

          -  Has a known hypersensitivities, allergies or contraindications to: nitinol, PTFE;
             aspirin, heparin, antiplatelet, anticoagulant or thrombolytic therapy; or
             anticoagulation or contrast media that is not amenable to pre-treatment;

          -  Has a known history of intracranial bleeding or aneurysm, myocardial infarction or
             stroke within the last 12 months

          -  Pregnant or nursing

          -  Untreated flow-limiting aortoiliac occlusive disease

          -  Has renal failure (eGFR &lt; 30mL/min)

          -  Major distal amputation (above the transmetatarsal) in the study or non-study limb

          -  Patient has had a revascularization procedure on the target limb within 30 days

          -  Patient has a planned amputation of the target limb

          -  Previous bypass surgery on the target limb

          -  Patient is participating in another clinical study for which follow-up is currently on
             going.

          -  Patient has a condition that in the view of the investigator precludes participation
             in this study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>78</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>PQ Bypass, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess the safety and performance of the PQ Bypass System to access, deliver guidewires
      and implant stent grafts for a percutaneous fem-pop bypass.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02471638</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>James Joye, MD</name>
      <address>PQ Bypass, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>